Prior Authorization Form

Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information	
Patient Name:		Prescriber Name:	
Health Plan Name:		Prescriber Address:	
Patient Insurance Id:			
Patient Date of Birth:		Prescriber Phone:	( )
Patient Phone:		Prescriber Fax:	( )
		Prescriber Specialty:	
		Prescriber DEA:	
		Prescriber NPI:	

Medication & Medical Information	
Requested Drug(s) & Strength(s):	[ ] Mekinist 0.5 mg tablet [ ] Mekinist 2 mg tablet
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	

Questionnaire

Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)

[ ] Yes

[ ] No

Q2: Is the member currently treated with this medication? (Check only one that apply)

[ ] Yes (please list start date of therapy (month/day/year)) _____

(*Required)

[ ] No

Q3: What is the member's diagnosis? (Check only one that apply)

[ ] Melanoma

[ ] Locally advanced or metastatic Anaplastic Thyroid Cancer (ATC)

[ ] Metastatic Non-small Cell Lung Cancer (NSCLC)

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q4: Request meets which of the following: (Check only one that apply)

[ ] Request is for the treatment of unresectable or metastatic melanoma

[ ] Request is for adjuvant treatment for melanoma

[ ] Other (please provide clinical rationale for the request) _____ (*Required)

Q5: What is the member's diagnosis? (Check only one that apply)

[ ] Melanoma

[ ] Locally advanced or metastatic Anaplastic Thyroid Cancer (ATC)

[ ] Metastatic Non-small Cell Lung Cancer (NSCLC)

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q6: Request meets which of the following: (Check only one that apply)

[ ] Request is for the treatment of unresectable or metastatic melanoma

[ ] Request is for Adjuvant Treatment for Melanoma

[ ] Other (please provide clinical rationale for the request) _____ (*Required)

Q7: Does the member have involvement of lymph nodes following complete resection? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q8: Is the requested medication will be used in combination with Tafinlar (dabrafenib)? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q9: Member's cancer is BRAF V600E or V600K mutant type as detected by a U.S. Food and Drug Administration (FDA)-approved test (THxID-BRAF Kit) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)? (Check only one that apply)

[ ] Yes (please specify mutation type and date of lab test) _____ (*Required)

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q10: Member's cancer cannot be treated with standard locoregional treatment options? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q11: Members cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)? (Check only one that apply)

[ ] Yes (please specify mutation type and date of lab test) _____
(*Required)

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q12: Is the requested medication will be used in combination with Tafinlar (dabrafenib)? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q13: Is the requested medication prescribed by or in consultation with an oncologist. (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group or its designated representatives may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	